Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Result Centre

Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)

Watch hVIVO’s Capital Markets Day 2022 presentation here.

Who Are We?

We are a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services for its broad and longstanding client base of biopharma companies

Results Archive

2023
2022
2021
2020
Archive

Performance in H1 2023:

Yamin 'Mo' Khan

CEO at hVIVO

"The first half of 2023 has delivered another period of excellent growth and progress towards our goal of establishing a long-term sustainable growth model. The increasing number of trials, as well as the growing volunteer cohorts and expanding use cases, highlights that the human challenge market is experiencing a strong growth trend that we strongly believe will continue over the long term. The outlook for the business is extremely positive, as our new state-of-the-art facility sets us up to accelerate our growth over the long term. We are delighted to increase our revenue guidance and EBITDA margin guidance for 2023. Finally, I would like to thank our staff for their continued dedication and boundless enthusiasm as we progress towards our vision to transform global healthcare."

Latest Investor Presentation

Example Stat
0
Example Stat
0
Example Stat
0
Example Stat
0

H1 23 Revenue

£0M

H1 23 EBITDA Margin

0%

Cash 30 June 2023

£0M

2023 Revenue Target (exluding other income)

£0M

Our 4 Points for Investment

Strong market dynamics

1

Scalable infrastructure

2

Trusted Partner

3

Orderbook growth

4

Our values

At hVIVO, our values are more than just words. They are what define us.

01

One Team

We are a diverse group of individuals working for one team to achieve common goals. Each one of us plays a crucial role in the team's success. We are committed to each other and the team. We learn from our failures together and celebrate our successes together. Diversity and inclusion are at the core of our organisation, and we consider our clients’ success as our own.

02

Growth

We are dedicated to the growth of our colleagues, customers and shareholders. We are committed to our personal growth and the development of our colleagues. We aim to grow our client base and the value of their products. We will repay the trust of our shareholders in achieving greater returns on their investment. We will achieve this by creating a culture of intellectual freedom across the organisation.

03

Integrity & Welfare

We take personal ownership of our actions and always act in ways that builds trust and respect with all our stakeholders. We pride ourselves in maintaining the welfare and the rights of all individuals and ensuring the best outcomes for our volunteers and patients. We are honest, have strong moral and ethical principles and are reliable and consistent in our delivery.

04

Innovation & Agility

We are pioneering in our approach, always curious. We use our unique scientific expertise to guide our client’s towards successful outcomes. We embrace new opportunities and rise to new challenges. Our agility allows us to redefine our markets and be highly responsive to our clients’ requirements.

Quick Links

chevron-downcross-circle